Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani, Hans-Günter Derigs, Sergey Kravchenko, Jack W. Singer, Panteli Theocharous, Lixia Wang, Mariya Pavlyuk, Kahina M. Makhlouf, Bertrand Coiffier
- This post hoc analysis of a phase 3 trial explored the effect of pixantrone in patients (50 pixantrone, 47 comparator) with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) confirmed by centralized histological review. Patients received 28-d cycles of 85 mg/m2 pixantrone dimaleate (equivalent to 50 mg/m2 in the approved formulation) on days 1, 8 and 15, or comparator. The population was subdivided according to previous rituximab use and whether they received the study treatment as 3rd or 4th line. Median number of cycles was 4 (range, 2–6) with pixantrone and 3 (2–6) with comparator. In 3rd or 4th line, pixantrone was associated with higher complete response (CR) (23·1% vs. 5·1% comparator, P = 0·047) and overall response rate (ORR, 43·6% vs. 12·8%, P = 0·005). In 3rd or 4th line with previous rituximab (20 pixantrone, 18 comparator), pixantrone produced better ORR (45·0% vs. 11·1%, P = 0·033), CR (30·0% vs. 5·6%, P = 0·093) and progression-free survival (median 5·4 vs. 2·8 months, hazard ratio 0·52, 95% confidence interval 0·26–1·04) than the comparator. Similar results were found in patients without previous rituximab. There were no unexpected safety issues. Pixantrone monotherapy is more effective than comparator in relapsed or refractory aggressive B-cell NHL in the 3rd or 4th line setting, independently of previous rituximab.
MetadatenAuthor: | Ruth Pettengell, Catherine Sebban, Pier Luigi Zinzani, Hans-Günter Derigs, Sergey Kravchenko, Jack W. Singer, Panteli Theocharous, Lixia Wang, Mariya Pavlyuk, Kahina M. Makhlouf, Bertrand Coiffier |
---|
URN: | urn:nbn:de:hebis:30:3-436853 |
---|
DOI: | https://doi.org/10.1111/bjh.14101 |
---|
ISSN: | 1365-2141 |
---|
ISSN: | 0007-1048 |
---|
Pubmed Id: | https://pubmed.ncbi.nlm.nih.gov/27118109 |
---|
Parent Title (English): | British journal of haematology |
---|
Publisher: | Wiley-Blackwell |
---|
Place of publication: | Oxford [u. a.] |
---|
Document Type: | Article |
---|
Language: | English |
---|
Date of Publication (online): | 2017/06/08 |
---|
Year of first Publication: | 2016 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2017/06/08 |
---|
Tag: | B-cell non-Hodgkin lymphoma; pixantrone; post hoc study; rituximab; salvage therapy |
---|
Volume: | 174 |
---|
Issue: | 5 |
---|
Page Number: | 8 |
---|
First Page: | 692 |
---|
Last Page: | 699 |
---|
Note: | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes |
---|
HeBIS-PPN: | 420978917 |
---|
Institutes: | Medizin / Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (English): | Creative Commons - Namensnennung-Nicht kommerziell 4.0 |
---|